J&J's Caplyta shows rapid improvement in bipolar mania in Phase 3 study
Johnson & Johnson announced that its drug Caplyta (lumateperone) demonstrated a statistically significant and rapid reduction in manic symptoms at Week 3 in a pivotal Phase 3 study for bipolar mania. The drug was well-tolerated, with dry mouth and nausea being the most common adverse events.
Johnson & Johnson said on Sept 21 that Caplyta (lumateperone) showed significant and rapid improvement in bipolar mania in a pivotal Phase 3 study. The company said the drug demonstrated a statistically significant rapid reduction in manic symptoms at week 3. Johnson & Johnson added that Caplyta was well tolerated, with dry mouth and nausea the most common adverse events.